Drugs / CL20- 4i-EF1alpha-hgammac-OPT vector
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01306019 | Sep 2012 → Dec 2032 expected | T-B+ severe combined immunodeficiency due to gamma chain deficiency | National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CL20- 4i-EF1alpha-hgammac-OPT vector | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01306019 ↗ |
| Action | Restore | “lentiviral gene transfer treatment at restoring immune function” NCT01306019 ↗ |
| Route | Intravenous | “Transduced cell product administered intravenously over approximately 30 minutes” NCT01306019 ↗ |